New Data, New Directions in Managing Patients with or at High Risk of ASCVD

Live Broadcast
Information
October 17, 2020
12:45 PM - 01:45 PM CDT
Online
New Data, New Directions in Managing Patients with or at High Risk of ASCVD
Choose a format
Details
Presenters
Comments
  • Overview

    This highly interactive live broadcast will feature leading experts who will address the complex interrelationship of further reducing ASCVD event risk with adjunctive therapies to statin use. This activity will provide the opportunity for the multispecialty faculty and participants to work through complex issues that challenge healthcare providers in caring for patients with elevated atherogenic cholesterol, triglycerides, and diabetes, many of whom have been suboptimally managed and continue to be at risk of advancing cardiovascular disease.

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Discuss recent cardiovascular outcomes trial results and their clinical implications in reducing ASCVD events
    • Assess the clinical utility of statin-adjunct therapies for ASCVD event reduction
    • Apply recent randomized clinical trial and evidence-based guidelines to reduce ASCVD risk
  • Target Audience

    This activity is designed to meet the educational needs of advanced-level clinicians, including cardiologists, internists, family practice physicians, lipidologists, and allied healthcare professionals. This audience is responsible for the prevention, diagnosis, and management of lipid disorders and cardiometabolic risk.

  • Accreditation and Credit Designation Statements

    The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.

    The AOA Bureau of OMED designates this live program activity for a maximum of 1.00 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

Facebook Comments

Details
Presenters
Comments
  • Overview

    This highly interactive live broadcast will feature leading experts who will address the complex interrelationship of further reducing ASCVD event risk with adjunctive therapies to statin use. This activity will provide the opportunity for the multispecialty faculty and participants to work through complex issues that challenge healthcare providers in caring for patients with elevated atherogenic cholesterol, triglycerides, and diabetes, many of whom have been suboptimally managed and continue to be at risk of advancing cardiovascular disease.

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Discuss recent cardiovascular outcomes trial results and their clinical implications in reducing ASCVD events
    • Assess the clinical utility of statin-adjunct therapies for ASCVD event reduction
    • Apply recent randomized clinical trial and evidence-based guidelines to reduce ASCVD risk
  • Target Audience

    This activity is designed to meet the educational needs of advanced-level clinicians, including cardiologists, internists, family practice physicians, lipidologists, and allied healthcare professionals. This audience is responsible for the prevention, diagnosis, and management of lipid disorders and cardiometabolic risk.

  • Accreditation and Credit Designation Statements

    The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.

    The AOA Bureau of OMED designates this live program activity for a maximum of 1.00 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free